Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is GBX 2,225 ($28.85).
Several equities research analysts recently commented on HIK shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 2,750 ($35.66) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 ($25.94) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Finally, Barclays reissued an “equal weight” rating and set a GBX 2,000 ($25.94) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 7th.
Get Our Latest Analysis on Hikma Pharmaceuticals
Insiders Place Their Bets
Hikma Pharmaceuticals Trading Up 0.4 %
LON:HIK opened at GBX 1,867 ($24.21) on Friday. Hikma Pharmaceuticals has a one year low of GBX 1,711 ($22.19) and a one year high of GBX 2,222 ($28.82). The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. The company’s 50-day simple moving average is GBX 1,923.14 and its 200 day simple moving average is GBX 1,911.35. The firm has a market capitalization of £4.14 billion, a P/E ratio of 2,786.57, a PEG ratio of 2.38 and a beta of 0.44.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- Is This Telehealth Stock a Buy After the Recent Pullback?
- The 3 Best Blue-Chip Stocks to Buy Now
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Ride Out The Recession With These Dividend Kings
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.